Azacitidine and Venetoclax Followed By Sequential Gilteritinib Is an Effective Alternative in Very Frail Patients with FLT3-Mutated Acute Myeloid Leukemia

被引：0

作者：

Nedumannil, Rithin ^{[1
,2
]}

Matley, Chelsea ^{[3
,4
]}

Bajel, Ashish ^{[3
,4
,5
]}

Levis, Mark J. ^{[6
]}

Wei, Andrew H. ^{[3
,4
,7
]}

机构：

[1] Peter Maallum Canc Ctr, Dept Clin Haematol, Doncaster, Australia

[2] Royal Melbourne Hosp, Doncaster, Australia

[3] Peter MacCallum Canc Ctr, Dept Clin Haematol, Melbourne, Australia

[4] Royal Melbourne Hosp, Melbourne, Australia

[5] Univ Melbourne, Dept Med, Melbourne, Australia

[6] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD USA

[7] Walter & Eliza Hall Inst Med Res, Melbourne, Australia

来源：

关键词：

D O I：

10.1182/blood-2024-194547

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：6060 / 6061

页数：2